CorMedix Inc. 4

Accession 0001144204-16-089619

$CRMDCIK 0001410098operating

Filed

Mar 21, 8:00 PM ET

Accepted

Mar 22, 5:28 PM ET

Size

19.9 KB

Accession

0001144204-16-089619

Form 4

Period: 2016-02-12

Director

Transactions

Award
Phantom Stock
2016-02-12+1,653→ 1,653 total
→ Common Stock, $0.001 par value per share (1,653 underlying)

Holdings

Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (30,000 underlying)
30,000
Stock Option (right to buy)
Exercise: $0.68Exp: 2022-12-05→ Common Stock, $0.001 par value per share (125,000 underlying)
125,000
Warrant (right to purchase Common Stock)
Exercise: $0.40From: 2012-11-13Exp: 2017-11-13→ Common Stock, $0.001 par value per share (25,000 underlying)
25,000
Stock Option (right to buy)
Exercise: $5.62Exp: 2025-03-01→ Common Stock, $0.001 par value per share (50,000 underlying)
50,000
Stock Option (right to buy)
Exercise: $0.28Exp: 2021-11-21→ Common Stock, $0.001 par value per share (15,000 underlying)
15,000
Phantom Stock
→ Common Stock, $0.001 par value per share (594 underlying)
594
Stock Option (right to buy)
Exercise: $1.91Exp: 2026-02-21→ Common Stock, $0.001 par value per share (75,000 underlying)
75,000
Common Stock, $0.001 par value per share
53,223
Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (150,000 underlying)
150,000
Stock Option (right to buy)
Exercise: $0.90Exp: 2023-03-20→ Common Stock, $0.001 par value per share (100,000 underlying)
100,000
Stock Option (right to buy)
Exercise: $0.29Exp: 2022-01-06→ Common Stock, $0.001 par value per share (5,000 underlying)
5,000

Footnotes (8)

[F1]These options vested 100% on January 10, 2014.
[F2]These options vest in full on the first anniversary of the date of grant.
[F3]These options vest quarterly over two years.
[F4]These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
[F5]On November 13, 2012, the reporting person acquired in a private placement $10,000 of (a) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share, and (b) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
[F6]The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
[F7]Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo
[F8]These shares were credited automatically to the reporting person's account pursuant to the reporting person's election to defer the receipt of cash compensation of director's fees.

Documents

1 file

CorMedix Inc.

CIK 0001410098

Entity typeoperating

IncorporatedDE